Showing 6831-6840 of 7932 results for "".
- Can Turning Off a Mutation Causing Wrinkling and Hair Loss Reverse the Processes? New Mouse Model Says Yeshttps://practicaldermatology.com/news/can-turning-off-a-mutation-causing-wrinkling-and-hair-loss-reverse-the-processes-new-mouse-model-says-yes/2457680/A new mouse model may one day allow scientists to reverse age-associated wrinkles and hair loss. When a mutation leading to mitochondrial dysfunction is induced, the mouse develops wrinkled skin and extensive, visible hair loss in a matter of weeks, but when the mitochondrial function is
- Game On: Head-to-head Trials to Enhance Competition in PsO Markethttps://practicaldermatology.com/news/head-to-head-trials-to-enhance-competition-in-pso-market/2457684/An increase in head-to-head trials will enhance the competition within the psoriasis market, according to
- BioPharmX: FDA Grants CARC Waiver; Post-Hoc Analysis for BPX-01 Completehttps://practicaldermatology.com/news/biopharmx-fda-grants-carc-waiver-post-hoc-analysis-for-bpx-01-complete/2457686/The FDA has waived its requirement for a dermal carcinogenicity study for BPX-01 from BioPharmX Corporation, eliminating several years of non-clinical research normally required for FDA review. BPX-01, a novel topical gel formulation of minocycline for the treatment of inflammatory
- Breaking News: Galderma Skinpact Awards Deadline Extended!https://practicaldermatology.com/news/breaking-news-galderma-skinpact-awards-deadline-extended/2457683/The new deadline for the Galderma Skinpact Awards is July 31, 2018. The awards are a social responsibility program by Galderma International in partnership with the Canadian Dermatology Association, and the Women's Dermatolo
- Trevi Therapeutics Appoints Yann Mazabraud as Chief Commercial Officerhttps://practicaldermatology.com/news/trevi-therapeutics-appoints-yann-mazabraud-as-chief-commercial-officer/2457685/Trevi Therapeutics, Inc. has named Yann Mazabraud as its Chief Commercial Officer and Head of International. Mr. Mazabraud will join Trevi’s senior management team and be responsible for overseeing Trevi’s commercial strategy and international operations.
- AD Takes Big Toll on QOLhttps://practicaldermatology.com/news/ad-takes-a-big-toll-on-qol/2457691/Itch, dryness and other eczema symptoms negatively affect quality of life, according to a new study published in the Annals of Allergy, Asthma and Immunology. Of 602 adults with eczema, symptoms that were the bigg
- Cynosure Launches TempSure Vitalia for Feminine Wellnesshttps://practicaldermatology.com/news/cynosure-launches-tempsure-vitalia-for-feminine-wellness/2457696/Hologic's Cynosure division has launched TempSure™ Vitalia in North America. TempSure Vitalia is an FDA-cleared and Health Canada-approved advanced radiofrequency treatment that delivers therapeutic heat to internal
- Sensus Healthcare Forms Strategic Agreement with SkinCure Oncologyhttps://practicaldermatology.com/news/sensus-healthcare-forms-strategic-agreement-with-skincure-oncology/2457697/Sensus Healthcare, Inc., which specializes in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), formed a strategic agreement focused on marketing the SRT-100 Vision with SkinCure Oncology, a leading turnkey provider
- Fourth Generation Retinoid Shows Promise in Acne Trialshttps://practicaldermatology.com/news/fourth-generation-retinoid-shows-promise-in-acne-trials/2457699/New research reveals that trifarotene, a fourth-generation retinoid with potent and selective activity against only one particular retinoic acid receptor, may have an improved efficacy and safety profile compared with less selective r
- XELJANZ Receives EU Marketing Authorization for Adults with Active PsAhttps://practicaldermatology.com/news/xeljanz-receives-eu-marketing-authorization-for-adults-with-active-psa/2457706/The European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) in combination with methotrexate (MTX) for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease-mod